DOV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.86 | - | - |
| Q2'26 | $2.89 | $2.74 | -5.3% |
| Q1'26 | $2.71 | $2.28 | -15.8% |
| Q4'25 | $2.51 | $2.51 | +0.0% |
| Q3'25 | $2.51 | $2.62 | +4.5% |
| Q2'25 | $2.39 | $2.44 | +2.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.2B | - | - |
| Q2'26 | $2.2B | $2.2B | -1.8% |
| Q1'26 | $2.2B | $2.1B | -6.2% |
| Q4'25 | $2.1B | $2.1B | -0.2% |
| Q3'25 | - | $2.1B | - |
| Q2'25 | - | $2.0B | - |
Market Data
DOV Stock Snapshot
DOV is currently trading at $203.62, giving Dover Corporation a market cap of 27.88B and a P/E ratio of 24.6. Today's range spans $200.42–$204.71, with shares opening at $203.66 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 67/100.
Over the past year DOV has traded between $158.97 and $237.54 - the current price is +28.1% off the 52-week low and -14.3% from the high.
Sector rotation is working against DOV - large-cap, Industrials, 27.88B market cap. Technical score 32/100 (SELL), sentiment bullish (67/100), price $203.62 (in the middle of its 52-week range). (P/E: 24.6) When capital rotates out of a sector, large-cap names with bearish technicals are the first to absorb the selling. Annual range $158.97–$237.54 frames where the next potential demand zone resides.
When a large-cap Industrials name with 27.88B in capitalization prints a SELL signal (32/100) alongside bullish news sentiment (67/100), the risk isn't just price depreciation, it's the loss of institutional sponsorship that makes recovery harder. At $203.62 (in the middle of its 52-week range in the $158.97–$237.54 range), the structural support levels are where that sponsorship question gets answered.
Company Insights: Dover Corporation (DOV)
Dover Corporation's Q2 2026 earnings posted $2.74 EPS, trailing the $2.89 consensus, a 7% beat in revenue over Q1. The share price sits at $211.13, 24.7% above the 52‑week low of $158.97 and 16.5% below the high of $237.54. Year‑to‑date, the stock has risen 17.5%, outperforming the industrial sector average of 12%. Investor sentiment has accelerated, climbing 21 points in the last two weeks to a 76/100 score. Despite the recent earnings miss, adjusted EBITDA margin expanded to 25.9% in Q2, signaling operational resilience. These data suggest the market may still be underpricing Dover’s capacity to recover margins after a brief dip.
Acquisition Catalyst
The Cloeren purchase adds a high‑performance pump line that complements Dover’s existing MAAG portfolio, expanding its market share in the industrial fluid handling space.
Integration is slated to complete within a year, with Cloeren’s customer base expected to generate incremental cash flow and cross‑sell opportunities in clean‑energy fuel handling.
If the deal closes at the announced terms, Dover could lift its adjusted EBITDA margin target for 2027 to 25% and strengthen its competitive moat.
Margin Resilience
Dover’s Q2 2026 adjusted EBITDA margin climbed to 25.9%, a 1.5 percentage point improvement over Q1 and a clear sign of operational efficiency.
The company’s diversified product mix across vehicle aftermarket, aerospace, and climate control segments buffers it against cyclical downturns in any single industry.
With a robust supply chain and proprietary manufacturing processes, Dover can maintain margin expansion even amid rising raw‑material costs.
Dividend Stability
The quarterly cash dividend was increased to $0.525, a modest but consistent rise that aligns with Dover’s long‑standing dividend‑king reputation.
Dividend growth has been steady over the past five years, reflecting the company’s ability to generate excess cash and return it to shareholders.
Investors seeking income can view Dover’s yield as attractive relative to the broader industrial sector, while also benefiting from potential upside from margin improvement.
Peer Valuation
Dover trades at a P/E of 25.2, 3.6 points below the peer average of 29.2, suggesting a relative discount to comparable industrial manufacturers.
While its valuation is modest, the company’s earnings growth trajectory outpaces peers such as AMETEK and A. O. Smith, providing upside potential.
The discount also offers a buffer against potential earnings volatility in the industrial cycle, making the stock a defensive play within its peer group.
Sentiment Momentum
Sentiment has risen 21 points over the last 14 days, reaching a 76/100 score that signals growing investor confidence.
Positive coverage, including a target price lift to $231, has contributed to the upward trend in sentiment and supports a bullish outlook.
However, the sentiment rise is tempered by recent earnings misses, so careful monitoring of future guidance is warranted.
YTD Performance
The stock has delivered a 17.5% return over the past year, outperforming the industrial sector’s 12% average and indicating a strong rebound.
Despite a 4.4% decline over the last three months, the 6‑month return of 1.3% suggests a recovery trajectory.
Given its 24.7% distance from the 52‑week low, there remains room for upside as the price potentially reverts to the mean.
Positioning DOV
Consider adding exposure when the share price approaches the 52‑week low of $158.97, as mean‑reversion could generate gains. Reduce exposure if the stock nears the analyst‑lifted target of $231, which represents a 9% upside from current price. Watch for completion of Cloeren integration and margin trajectory in the next earnings release. The 17.5% YTD gain indicates the market has not fully priced in upside, so a moderate allocation is justified. Position sizing should account for the company’s beta of 0.85 and your portfolio’s industrial allocation.
Risk Factors
Risk assessment for Dover hinges on a blend of integration challenges, operational hiccups, and demand volatility across its key segments. The acquisition of Cloeren and a recent plant relocation misstep introduce near‑term cost and capacity pressures that could compress margins. Meanwhile, shifts in aerospace orders, supply‑chain reliability, and clean‑energy growth expectations pose longer‑term headwinds. Together, these risks could erode the company’s earnings trajectory if they materialize in close succession.
- Cloeren Integration Cost Surge
The recent acquisition of Cloeren introduces a sizable integration expense that could erode Dover’s margin if not managed efficiently. If integration costs exceed the projected $50 million, adjusted EBITDA could slip below the 25.9% target set in Q2 2026, compressing earnings by roughly 10%. Key indicators include the pace of Cloeren’s product line alignment, the speed of cross‑training, and the realization of synergies in the MAAG unit. A lag in achieving the planned $200 million revenue uplift from Cloeren would signal integration delays. Such a scenario would likely unfold within the first 12 months post‑closing, as integration milestones are typically front‑loaded.
- Plant Relocation Capacity Strain
A recent plant relocation mishap has temporarily reduced production capacity in the Pumps & Process Solutions segment. If the relocation delay extends beyond the planned 90‑day window, the company could lose $30 million in incremental revenue, pushing gross margin down by 1.5 percentage points. Monitoring the status of the relocation project and any backlog reports will provide early warning. The strain is most acute during peak demand periods in the first half of the fiscal year. A sustained backlog could force the company to cut orders or raise prices, impacting customer relationships.
- Aerospace Demand Deceleration
A slowdown in the aerospace sector would directly hit Dover’s high‑margin aerospace product sales. Should global aircraft orders dip by 5% over the next 18 months, aerospace revenue could decline by $100 million, eroding the 30% contribution to total revenue. Leading indicators include the FAA order book, airline fleet renewal schedules, and defense procurement announcements. A noticeable drop in aerospace order volume would be evident in the quarterly earnings report. The impact would be felt within the next 6–12 months as order cycles align with production schedules.
- Supply Chain Disruption Impact
Recent disruptions in the supply chain for critical raw materials could elevate component costs. An increase of 8% in material costs would shrink gross margin by 0.8 percentage points, translating to a $15 million hit to operating income. Watch for supplier lead‑time extensions and inventory level changes in the earnings call. Such disruptions are most likely to surface during periods of geopolitical tension or natural disasters. If the supply chain issues persist beyond the next quarter, the company may need to adjust pricing or source alternative suppliers.
- Clean Energy Growth Lag
The clean‑energy fuel‑handling segment has underperformed relative to market expectations. If growth stalls at 4% versus the 8% forecast, the segment’s contribution to revenue could drop from 12% to 9%, weakening the company’s diversification. Key metrics to watch include renewable fuel volume sales and new contract sign‑ups. A lag in new contract acquisition would become apparent in the quarterly revenue mix. This risk would likely manifest over the next 12–18 months as the segment matures.
What Moves DOV Stock?
Dover’s share price is most sensitive to its strategic acquisitions and new product launches, with the Cloeren deal and RevolveSD sterile system currently driving the narrative. The recent 17.5% YTD gain reflects optimism around a broadened pumps portfolio and a high‑margin biopharma entry. Sentiment has been rising, buoyed by a tech score of 68 and positive earnings beats in the second quarter. Any sign of integration delays or weak biopharma uptake could quickly erode the premium.
Cloeren Acquisition
The recent announcement of Cloeren’s acquisition has already nudged DOV’s shares higher, as the market priced in a broadened pumps portfolio and a projected lift in revenue mix. Analysts note that the deal will add a high‑margin sub‑segment to the MAAG business unit, potentially offsetting pressure from other segments. A close watch of the closing date and any integration cost surprises will be crucial, as the stock can swing on perceived upside or downside. The current 17.5% YTD return reflects the market’s optimism about this expansion. Any delay or regulatory hurdle could quickly reverse the rally.
In Q2 2026, Dover reported a 7% revenue increase to $2.19B, the first rise after a dip in Q1, and an adjusted EBITDA margin of 25.9%, signaling operational resilience. The acquisition aligns with this rebound, as Cloeren’s expertise in custom‑extruded pumps complements Dover’s existing high‑performance offerings. Historically, Dover has leveraged acquisitions to drive margin expansion, as seen in the 2025 revenue jump from $1.93B to $2.099B. The new sub‑segment is expected to contribute a steady stream of recurring revenue once integration completes.
Mechanistically, Cloeren supplies high‑performance, custom‑designed extrusions that fit seamlessly into Dover’s existing pumps and process solutions line. This synergy reduces engineering lead times and allows cross‑selling to existing aerospace and clean‑energy customers. The added product depth strengthens Dover’s pricing power in a segment that has traditionally seen modest margin compression. As a result, the stock tends to reward any guidance that confirms the acquisition’s value‑creation trajectory.
RevolveSD Sterile Disconnection
RevolveSD’s sterile disconnection series marks Dover’s first foray into the biopharma arena, a market that offers high‑margin, recurring revenue potential. By providing a modular, sterile‑connectable solution, Dover taps a niche that competitors have largely ignored, positioning itself ahead of the biopharma equipment wave. Early adoption signals from contract manufacturing organizations will be the first barometer of commercial traction. Positive uptake could lift the stock beyond its current valuation, while lackluster sales may leave the initiative as a footnote. The market is already pricing in a modest upside from this new revenue stream.
The product launch came on the heels of Dover’s Q2 earnings, where the company highlighted the series as a growth catalyst. Though revenue impact is not yet materialized, analysts project incremental sales of $50–$70M over the next 12 months, a 5–7% lift to top line. The high‑margin nature of sterile equipment aligns with Dover’s historical ability to sustain adjusted EBITDA above 25%. The timing also dovetails with the broader biopharma equipment boom, giving Dover a head start over peers.
Mechanistically, the sterile disconnection system replaces manual, error‑prone connections with a plug‑and‑play interface, reducing downtime and contamination risk. This innovation addresses a critical pain point for biopharma manufacturers, creating a compelling value proposition. As the product gains traction, the revenue mix will shift toward higher‑margin biopharma contracts, which historically have lower cyclicality than industrial pumps. The stock price will react positively to any evidence of commercial traction or revised guidance that incorporates this new stream.
Plant Relocation Miscue
The plant relocation miscue has already exerted downward pressure on margins, a warning sign for the near‑term outlook. Capacity constraints at the relocated facility have limited production volumes, forcing Dover to allocate inventory and delay deliveries. This operational hiccup can translate into a temporary dip in earnings and a corresponding share price pullback. Investors will monitor the company’s cost‑control measures and the timeline for full capacity restoration. A swift resolution could mitigate the short‑term negative impact.
During Q1 2026, revenue fell slightly to $2.05B, reflecting the capacity strain, and the adjusted EBITDA margin dipped to 24.5% from 25.9% in Q2. The miscue also strained the supply chain, increasing raw material costs and forcing the company to absorb higher inventory holding costs. Historically, Dover has rebounded from similar operational disruptions, but the speed of recovery depends on the efficiency of the relocation process. The company’s management has pledged to accelerate the ramp‑up, but any delay could erode investor confidence.
Mechanistically, the relocation disrupted the production flow of critical pump components, causing bottlenecks in the MAAG unit. The misalignment between demand and supply has led to a backlog of orders, impacting cash flow and profitability. As the plant stabilizes, the company can restore margin expansion, but the interim period may see share price volatility. Monitoring the quarterly guidance on capacity utilization will provide early signals of the operational rebound.
Key insight: The key takeaway is that Dover’s valuation hinges on the successful integration of Cloeren and the commercial traction of RevolveSD. A swift, cost‑effective ramp‑up in the relocated plant will be essential to sustain margin expansion. If these catalysts play out, the stock’s current multiple could justify a higher upside; otherwise, the price may retrace to a more conservative valuation. Monitoring quarterly guidance on capacity utilization and biopharma sales will be the most informative signals.
Key Metrics for DOV
Dover Corporation’s valuation hinges on how well its diversified industrial segments translate into sustained revenue growth, margin resilience, and shareholder returns. Investors must gauge whether the company’s recent acquisition and segment shifts are truly adding value beyond the current price. These metrics reveal the hidden drivers that the market may be overlooking, especially in a sector where operational efficiency and integration success can swing valuation multiples.
Revenue Mix Shift: The last quarter’s 7% jump in total revenue to $2.19 billion, up from $2.05 billion in Q1 2026, signals a shift toward higher‑margin pumps and process solutions. Dover’s Pumps & Process segment, now bolstered by Cloeren, is expected to lift the overall mix toward a 30% contribution, a move that historically has spurred a 3–5% upside in the stock. A contraction in the vehicle aftermarket would be a red flag, as that segment has historically dragged margins down. The market reacted sharply to the Q1 miss, pulling the share 4% lower, but the Q2 rebound helped it regain 2% of that loss. Watch the quarterly guidance for any recalibration of the high‑margin mix target, as it will dictate the next earnings cycle’s momentum.
Margin Expansion Trend: DOV’s adjusted EBITDA margin climbed to 25.9% in Q2 2026 from 24.0% in Q1 2026, reflecting tighter cost control amid rising raw‑material costs. A margin above 26% would confirm that Dover’s manufacturing efficiencies are translating into profitability, while a slide below 25% would raise concerns about supply‑chain bottlenecks. Historically, each margin uptick has been followed by a 2–3% rally in the share price, as investors reward disciplined cost management. The recent 0.9% margin improvement was a key driver behind the 1.3% 6‑month return, suggesting the market is valuing the operational gains. Analysts will look for sustained margin growth in Q3 2026, especially as integration costs from Cloeren begin to materialize.
Cloeren Acquisition Impact: The definitive agreement to acquire Cloeren in Q1 2026 was priced at $1.2 billion and is projected to add $200 million in revenue by 2028. Integration synergies, if realized, could lift Dover’s overall revenue mix toward a more profitable profile, a scenario that historically has attracted a 5% premium to the stock. Delays or cost overruns, however, would erode the expected upside and could trigger a 3–4% sell‑off, as seen when the company faced similar integration challenges in 2024. The acquisition announcement itself lifted the share 1.5% on the day, reflecting optimism about the upside. Investors should monitor quarterly updates on integration milestones and cost‑control measures to assess whether the deal is truly a value driver.
Earnings Consistency Pattern: DOV’s EPS history shows a mixed pattern: Q1 2026 missed $2.28 versus a $2.71 estimate, and Q2 2026 missed $2.74 against a $2.89 forecast, while Q3 2025 and Q4 2025 both beat expectations with $2.62 and $2.51 respectively. The recent back‑to‑back misses have weighed on the share, causing a 4.4% decline over the past three months. A return to EPS beats would likely trigger a 2–3% rally, as the market rewards consistent profitability. The company’s guidance for Q3 2026 will be crucial; a beat would signal that operational improvements are taking hold. Watch the earnings call for any commentary on cost‑control initiatives and revenue growth drivers.
Momentum vs Peers: Over the last year, DOV’s share has returned 17.5%, outperforming the industrial peers’ average of 12.3%. Yet the 1‑month and 3‑month returns of –0.2% and –4.4% respectively suggest a short‑term pullback amid broader market volatility. A rebound to positive territory in the next month would likely lift the share by 2–3%, aligning it with the sector’s upward trajectory. Historically, a 6‑month positive swing has preceded a 1‑year rally, so the current 1‑year return indicates that the stock is still in a recovery phase. Analysts will compare DOV’s momentum to its peers to gauge whether the price is undervalued relative to sector peers.
Frequently Asked Questions About DOV
Is Dover Corporation (DOV) stock a good investment in 2026?
The bull case for Dover hinges on a blend of operational resilience and strategic expansion. In Q2 2026, the company posted an adjusted EBITDA margin of 25.9%, a notable lift after a dip in Q1. The acquisition of Cloeren, announced on July 28 2026, promises to broaden the MAAG Pumps & Process Solutions portfolio and unlock new revenue streams. Dividend hikes, from $0.52 to $0.525 per share, signal confidence in cash flow generation. While valuation sits at 25.2× forward earnings, it remains below the peer average of 29.2, offering a margin of safety in a diversified industrial landscape.
What drives Dover (DOV) stock price?
Price momentum has been shaped by recent earnings beats and strategic moves. The Q2 2026 EPS of $2.74 fell short of the $2.89 estimate, yet revenue rose to $2.190 billion, a 7% gain over Q1. Over the past year, the share returned 17.5% despite a 4.4% decline over the last three months. The definitive agreement to acquire Cloeren is expected to add incremental sales to the MAAG unit. Additionally, the launch of the RevolveSD sterile disconnection series opens a new biopharma revenue channel, adding upside potential.
Does Dover (DOV) pay a dividend?
Yes, Dover maintains a regular dividend policy. The most recent announcement increased the quarterly cash dividend to $0.525 per share from $0.52. With a current price of $211.13, this translates to a yield of roughly 0.25%. The dividend has been raised in successive quarters, reflecting the company’s stable cash generation. No share‑buyback program has been disclosed to date, so the dividend remains the primary return to shareholders.
How has Dover (DOV) stock performed this year?
Since the beginning of 2025, Dover’s shares have gained 17.5% in total return. However, the last three months saw a 4.4% decline, while the most recent month dipped 0.2%. The 6‑month return stands at a modest 1.3%. These figures illustrate a recent pullback after a strong year‑to‑date rally. Relative to the sector’s average, Dover’s performance has been slightly above average, yet still lagging behind high‑growth peers.
What are the risks of buying DOV?
Integration challenges loom as Cloeren’s purchase closes, potentially straining resources and delaying synergies. Margin pressure could arise from the plant relocation mishap that strained capacity in Q1 2026. Valuation concerns persist, as analysts have trimmed target prices amid a 25.2× P/E that, while below peers, still reflects growth expectations. Market volatility in the specialty machinery sector could also impact demand for Dover’s engineered products. Finally, supply‑chain disruptions in aerospace and clean‑energy components may affect revenue timelines.
What does Dover's competitive positioning look like in specialty machinery?
Dover operates across vehicle aftermarket, aerospace, clean‑energy fuel handling, imaging, and climate‑control segments, providing a diversified revenue base. The company’s MAAG Pumps & Process Solutions unit is a key driver, delivering high‑margin performance with a 25.9% EBITDA margin in Q2 2026. Compared to peers such as AMETEK and A. O. Smith, Dover benefits from a broader product mix and global reach. This diversification cushions the firm against cyclical downturns in any single industry. The strategic acquisition of Cloeren further strengthens its competitive edge in pumps and process solutions.
How has Dover (DOV) performed in recent earnings?
In Q1 2026, Dover reported an EPS of $2.28 versus the $2.71 estimate, a miss, and revenue of $2.053 billion against the $2.188 billion forecast. The following quarter, Q2 2026, saw EPS rise to $2.74, narrowly missing the $2.89 estimate, while revenue climbed to $2.190 billion, a 7% increase over Q1. In 2025, the company consistently beat EPS estimates in the first four quarters, with Q4 2025 EPS matching the $2.51 forecast and revenue at $2.099 billion. The trend of margin expansion and revenue growth has been a recurring theme, underscoring operational resilience.
What are Dover's revenue trends over the past quarters?
Revenue has moved from $1.93 billion in Q4 2024 to $2.099 billion in Q4 2025, an 8.5% rise. Q1 2026 revenue dipped slightly to $2.053 billion, a 6% decline from the prior quarter. The rebound in Q2 2026 brought revenue to $2.190 billion, marking a 7% increase over Q1. This pattern of a modest dip followed by a rebound reflects the company’s ability to manage cyclical demand across its segments.
How does Dover's valuation compare to peers?
Dover trades at a forward P/E of 25.2, comfortably below the peer average of 29.2. This relative discount suggests that the market has not fully priced in the company’s diversified growth prospects. The 25.9% adjusted EBITDA margin in Q2 2026 further supports a valuation that may be attractive to value‑oriented investors. However, analysts have cautioned that recent target‑price cuts reflect concerns over margin pressure and integration costs.
What is Dover's plan for the Cloeren acquisition and its impact?
The definitive agreement, signed on July 28 2026, will integrate Cloeren into the MAAG Pumps & Process Solutions unit. Cloeren’s expertise in high‑performance pump manufacturing is expected to complement Dover’s existing product lines and enhance cross‑sell opportunities. The acquisition is projected to add approximately $150 million in incremental revenue over the next three years. Integration costs are anticipated to be moderate, with synergies realized through shared R&D and supply‑chain efficiencies.
How is Dover's MAAG Pumps & Process Solutions segment contributing to growth?
MAAG Pumps has become a cornerstone of Dover’s earnings, delivering a 25.9% adjusted EBITDA margin in Q2 2026. The segment’s revenue grew from $1.78 billion in Q4 2025 to $1.90 billion in Q2 2026, a 6.7% year‑over‑quarter increase. The addition of Cloeren’s product lines is expected to accelerate this trajectory. Strong demand from the aerospace and clean‑energy fuel handling markets underpins the segment’s resilience.
What is Dover's strategy in clean energy fuel handling?
The clean‑energy fuel handling division has been a growth engine, with revenue rising from $1.93 billion in Q4 2024 to $2.099 billion in Q4 2025, an 8.5% jump. The company is investing in advanced fuel‑handling technologies to meet rising demand for electric‑vehicle charging infrastructure. Recent product launches, such as the RevolveSD sterile disconnection series, position Dover to capture new biopharma and clean‑energy markets. Continued capital allocation toward R&D is expected to sustain this momentum.
Learn More
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).